Zydus Cadila receives tentative approval from USFDA for Pemetrexed
Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells
Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells
Fingolimod is an immunomodulating drug. It is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis
The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The deal is to sell one of the two business undertakings of ZAHL for a lump sum consideration of Rs. 2921 crores on a cash free and debt free basis,
Subscribe To Our Newsletter & Stay Updated